at this time. The ICPT drug was accidentally found to help NASH while it was being investigated for autoimmune disorder.NIH is currently involved in researching the treatments which might benefit NASH.
Those with NASH are most of the time obese , have diabetes and elevated cholesterol levels. Liver biopsy is a simple procedure and can confirm NASH. As there was no treatment available for NASH, there was no need to do liver biopsy. We told these patients to simply monitor diet and waited for them to develop cirrhosis. Then these patients waited for liver transplantation and died while waiting..
Now with the ICPT drug being available, the doctors are going to encourage liver biopsies in suspected cases of NASH. It will be malpractice not to diagnose NASH if the effective treatment becomes available.
This is a very important breakthrough and ICPT needs much higher valuation. It was not ICPT who stopped the trial, it was NIH.
The patients with NASH will always need monitoring and treatment of the cholesterol level with or without treatment.
The elevation of cholesterol is transient and reversible side effect. Will need proper dietary management.
Lexapro causes elevation in cholesterol level.
The market for the liver disease is huge. That mad man has no idea about the deaths from liver disease specifically in the persons who had no history of alcoholism. The analysts have to come to grips with the market for these kind of life saving drugs.
on very small volume. There is no panic selling as the bashers try to portray. What a joke. Hedgies are the ones panicking as the retail has fully controlled the outcome.
Sentiment: Strong Buy
It is easy to understand why some folks are selling. Only smart shareholders like you are buying. It is not easy to buy however.
smart. The leader is now saying that the retail does not own much of WMIH. New trick to tell the retail that they have no voice. At least the judge has more sense on the board.
Sold and bought back in very small quantities. There seems to be stability in the WMIH market as the upward move continues. The volatility and manipulation has disappeared for now IMO. This indicates the confidence in the KKR deal.
MMs should bring it upto $ 5.00 now and may see a very small sell off if they get lucky. We know the real value is $ 25 to 50.00
It will be better for JPM to get in WMIH for its NOLS and be thankful to FDIC for free gift of WAMU. The beggers like JD never stop crying.
for each share of WMIH may be the ultimate buyout as the WMIH shareholders are going to hold onto their shares. With the target of $ 30.00 for KKR, it still amounts to only a buck per the old share.
Doxorubicin Hydrochloride Injection, USP has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma, and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types.
Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.